Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus CIK in wild-type EGFR lung adenocarcinoma
NCT02493582Phase 2Active, not recruiting
- Sponsor
- Changzhou First People's Hospital
- Start
- Jul 2015
- Primary completion
- Jul 2030
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
01
Overview
Phase 2, randomised, open-label trial of unmodified CIK in lung adenocarcinoma, sponsored by Changzhou First People's Hospital. Started Jul 2015; status: active, not recruiting.
02
Drugs
unmodified CIK
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT02493582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02493582.